Convidecia Air? is the first global aerosolized recombinant viral vector COVID-19 vaccine for inhalation, which can not only stimulate humoral and cellular immunity, but also induce mucosal immunity to achieve triple comprehensive protection efficiently without intramuscular injection. Notably, Convidecia Air? offers unique advantages, including safety, effectiveness, painlessness, convenience and availability. By leveraging the same adenovirus vector technological platform as the intramuscular Convidecia?, Convidecia Air? provides a noninvasive option that employs a nebulizer to convert liquid into an aerosol for inhalation through the mouth. Convidecia Air? is needle-free and can effectively trigger comprehensive immune protection in response to SARS-CoV-2.